Jonathan Kay to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Jonathan Kay has written about Tumor Necrosis Factor-alpha.
Connection Strength
0.873
-
Kay J, Cross RK, Feldman SR, Park Y, Hanauer SB. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
Score: 0.182
-
Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017 Mar; 16(3):289-302.
Score: 0.113
-
Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017 01; 76(1):4-6.
Score: 0.110
-
Smolen JS, Kay J, Doyle M, Landew? R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015 Jan 22; 17:14.
Score: 0.098
-
Smolen JS, Kay J, Matteson EL, Landew? R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8.
Score: 0.089
-
Smolen JS, Kay J, Landew? RB, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Zhou Y, Hsia EC, Doyle MK. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 Oct; 71(10):1671-9.
Score: 0.081
-
Smolen JS, Kay J, Doyle MK, Landew? R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18; 374(9685):210-21.
Score: 0.067
-
Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun; 43 Suppl 3:iii2-iii9.
Score: 0.047
-
Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 09; 69(9):1741-1750.
Score: 0.029
-
Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016 May; 75(5):791-4.
Score: 0.026
-
Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55.
Score: 0.022
-
Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM, Owen WF. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 2001 Mar; 59(3):990-1002.
Score: 0.009